Skip to content

Efficacy Evaluation of Conservative Treatment with Flurbiprofen Gel Patch Combined with Moxibustion for Knee Osteoarthritis

Efficacy Evaluation of Conservative Treatment with Flurbiprofen Gel Patch Combined with Moxibustion for Knee Osteoarthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121138
Enrollment
Unknown
Registered
2026-03-26
Start date
2026-03-31
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

Experimental group:Patients in the experimental group received topical flurbiprofen gel patch combined with moxibustion on the affected knee. Flurbiprofen gel patch, containing 40 mg of flurbiprofen p
Moxibustion alone control group:Heat-sensitive moxibustion was adopted. Moxibustion-sensitive points were detected around the knee joint in the region composed of Yinlingquan (SP9), Yanglingquan (GB34
Flurbiprofen patch alone control group:Patients in the experimental group received topical flurbiprofen gel patch combined with moxibustion on the affected knee. Flurbiprofen gel patch, containing 40

Sponsors

The First People's Hospital of Longquanyi District, Chengdu
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the Western medical diagnostic criteria for osteoarthritis (Orthopedics, People's Medical Publishing House); 2. No gender restriction, aged 18–60 years; 3. No use of other therapeutic drugs (such as analgesics, hormones) or surgical treatment within the past 1 month; 4. Voluntarily participate in and comply with the treatment protocol, with signed informed consent; 5. No severe neurological, psychiatric or somatic diseases.

Exclusion criteria

Exclusion criteria: 1. Received previous therapeutic interventions that may affect the efficacy; 2. Complicated with severe underlying diseases such as tumors, cardiovascular and cerebrovascular diseases, hematological diseases, and digestive system diseases; 3. Patients with hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) including loxoprofen and flurbiprofen; 4. Patients with asthma or allergic constitution to moxibustion.

Design outcomes

Primary

MeasureTime frame
Symptom improvement rate;

Secondary

MeasureTime frame
the Western Ontarioand McMaster Universities Osteoarthritis Index (WOMAC) score;VAS score;IL-1ß;TNF-a;

Countries

China

Contacts

Public ContactWu Linfeng

The First People's Hospital of Longquanyi District, Chengdu

gordonwlf@163.com+86 28 6823 8127

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026